Víctor Galán-Gómez

Víctor Galán-Gómez

Auto-generated profile, based on publicly available information

Víctor Galán-Gómez

Pediatric Hemato-Oncology Department, La Paz University Hospital, Madrid, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2020 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
PRPedro M Rubio
Pedro M Rubio
VGVictor Galán
Victor Galán
SRSonia Rodado
Sonia Rodado
DPDiego Plaza
Diego Plaza
LMLeopoldo Martinez
Leopoldo Martinez
Neuroblastoma causes 15% of cancer mortality in children. High risk neuroblastoma has poor prognosis, with high relapse rate and mortality despite multimodal treatment. 123-I-meta-iodo-benzyl-guanidine (mIBG) scintigraphy is one of the current standard diagnostic procedures in neuroblastoma. mIBG can also be used therapeutically, labeled with 131-I, as a radiopharmaceutical agent, delivering targeted radiotherapy to tumoral sites. But published data of this strategy show heterogeneous results. One concern is that in most reports the infused activity is only based in body-weight, which could lead to infra or over-treatment, depending on inter-patient variability in radiation absorption. Activity adjustment by whole-body dosimetry can be used to homogeneize the treatment. Also, mIBG avid tumors may lose avidness along the treatment. As mIBG is used both for treatment and response evaluation, this could result in undetected progressions in patients with apparent complete response. We present a retrospective single-center review of neuroblastoma patients who received therapeutic 131-I-mIBG, focusing on cases with dosimetry-adjusted activity. Dosimetry allowed for a more precise delivery of radiation, reducing 81.1% of deviation from absorption target of 4 Gray (Gy), from 23.4% (±0.936 Gy) to 4.4% (± 0.176 Gy). Patients who showed partial or complete response had better and longer survival. Relapse/progression in non-responders was an early event (within 3 months from treatment). We also present one case of progression with apparent complete response due to loss of mIBG avidness, detected in our series.

3 April 2022 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
AFAdrián Fernández
Adrián Fernández
Antonio Pérez MartínezAntonio Pérez Martínez
Antonio Pérez Martínez
AEAdela Escudero
Adela Escudero
IMIsabel Mirones
Isabel Mirones
BGBerta González
Berta González
LFLucía Fernández
Lucía Fernández
Natural killer group-2 member D (NKG2D) is an activating receptor expressed in cytotoxic lymphocytes that plays an important role in anti-tumor immunosurveillance [1]. By recognition of the stress-...

9 February 2024 in European Journal of Haematology
Verified
Journal Article
Closed access
CECarlos Echecopar
Carlos Echecopar
IAInés Abad
Inés Abad
VGVíctor Galán‐Gómez
Víctor Galán‐Gómez
YCYasmina Mozo del Castillo
Yasmina Mozo del Castillo
LSLuisa Sisinni
Luisa Sisinni
Antonio Pérez MartínezAntonio Pérez Martínez
Antonio Pérez Martínez

Verified
Journal Article
Open access
PDF file
VGVíctor Galán-Gómez
Víctor Galán-Gómez
NMNerea Matamala
Nerea Matamala
BRBeatriz Ruz-Caracuel
Beatriz Ruz-Caracuel
PVPaula Valle-Simón
Paula Valle-Simón
BOBárbara Ochoa-Fernández
Bárbara Ochoa-Fernández
AEAdela Escudero
Adela Escudero
Relapsed and refractory (R/r) disease in paediatric acute leukaemia remains the first reason for treatment failure. Advances in molecular characterisation can ameliorate the identification of genetic biomarkers treatment strategies for this disease, especially in high-risk patients. The purpose of this study was to analyse a cohort of R/r children diagnosed with acute lymphoblastic (ALL) or myeloid (AML) leukaemia in order to offer them a targeted treatment if available. Advanced molecular characterisation of 26 patients diagnosed with R/r disease was performed using NGS, MLPA, and RT-qPCR. The clinical relevance of the identified alterations was discussed in a multidisciplinary molecular tumour board (MTB). A total of 18 (69.2%) patients were diagnosed with B-ALL, 4 (15.4%) with T-ALL, 3 (11.5%) with AML and 1 patient (3.8%) with a mixed-phenotype acute leukaemia (MPL). Most of the patients had relapsed disease (88%) at the time of sample collection. A total of 17 patients (65.4%) were found to be carriers of a druggable molecular alteration, 8 of whom (47%) received targeted therapy, 7 (87.5%) of them in addition to hematopoietic stem cell transplantation (HSCT). Treatment response and disease control were achieved in 4 patients (50%). In conclusion, advanced molecular characterisation and MTB can improve treatment and outcome in paediatric R/r acute leukaemias.

21 February 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
CGCarlos Daniel Grasa
Carlos Daniel Grasa
BOBárbara Ochoa
Bárbara Ochoa
FBFernando Baquero-Artigao
Fernando Baquero-Artigao
SRSonsoles San Román
Sonsoles San Román
VGVíctor Galán‐Gómez
Víctor Galán‐Gómez
Antonio Pérez MartínezAntonio Pérez Martínez
Antonio Pérez Martínez

16 August 2023 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
VGVictor Galán
Victor Galán
CBCristina Belendez
Cristina Belendez
CECarlos Echecopar
Carlos Echecopar
PEPablo Estival
Pablo Estival
LSLuisa Sisinni
Luisa Sisinni
APAntonio Pérez-Martínez
Antonio Pérez-Martínez
Data on treosulfan-based conditioning regimens are little by little increasing, and the benefits of this approach are consistent, particularly regarding acute toxicity. This study aims to describe the results of treosulfan-based conditioning regimens in children, focusing on toxicity and outcomes when used to treat both malignant and non-malignant diseases. Retrospective observational study on pediatric patients treated in Spain with treosulfan-based conditioning regimens before hematopoietic stem cell transplantation (HSCT), based on data collection from electronic clinical records. One hundred and sixty treosulfan-based conditioning HSCTs to treat non-malignant diseases (n=117) or malignant diseases (n=43) in 158 children and adolescents are reported. Median age at HSCT was 5.1 years (IQR: 2-10). The most frequent diagnoses were primary immunodeficiency (n=42; 36%) and sickle cell disease (n=42; 36%) in the non-malignant cohort and acute lymphoblastic leukemia (n=15; 35%) in the malignant cohort. Engraftment occurred in 97% of the patients. There was a longer median time to neutrophil engraftment (17 vs. 14 days; p=0.008) and platelet engraftment (20 vs. 15 days; p=0.002) in the non-malignant cohort. The 1-year cumulative incidence of VOD was 7.98 (95%CI [4.6-13.6]), with no significant differences between cohorts. The 1-year cumulative incidence of grade III-IV aGvHD was higher in the malignant cohort (18% vs. 3.2%; p=0.011). Overall, cGvHD was more frequently observed in the malignant cohort for both total incidence (9 vs. 3%; p<0.001) and 2-year cumulative incidence of total cGvHD (16 vs. 1.9%; p<0.001). The 2-year cumulative TRM was 15%, with no differences between cohorts. 5-year Overall Survival was 80% (95%CI [72-86]) and was higher in the non-malignant cohort (87 vs. 61%; p=0.01). The 2-year cumulative incidence of relapse in the malignant cohort was 25%. 5-year cumulative GRFS rate was 60% (95%CI [51-70]) and was higher in the non-malignant cohort (72 vs. 22%; p<0.001). The treosulfan-based radiation-free conditioning regimen is feasible, achieving a high engraftment rate and 5-year overall survival. A treosulfan-based conditioning regimen is an emerging option for the first HSCT in non-malignant diseases.